ESMO Summer Educational Conference, ESEC

May 19, 2003

You are invited... to report on one of Europe's most important educational cancer conferences

There are few fields in clinical medicine that are expanding as rapidly as oncology. Don't miss your chance to report on the latest updates in treatment for cancer patients.

This 'one-step educational experience' will focus on conventional medical oncology such as gynecological and colorectal tumors, as well as emerging fields like psycho-oncology and quality-of-life. ESEC will confront difficult situations and areas of treatment that require special attention. It will address the question of what patients need from their oncologists and encourage open discussion on controversial issues such as Hormone Replacement Therapy, complementary medicine, screening, and new treatments.

Supported by various European cancer groups, a Second European Patient Seminar (Saturday, 21 June 2003) will attempt to move beyond patient-physician communication to patient-physician partnership. Reflecting the true spirit of partnership,Come join us and be the first to know what patients want from their ideal cancer doctor, what doctors expect from patients, what can be done to improve communication, reinforce partnership, and ultimately improve healthcare services for cancer patients.

Planned Press Activities:

ESMO President and ESEC Working Party Meet the Press
Saturday, 21 June, 09.00-10.15

Press Conference:
Saturday, 21 June, 12.30-13.30

Free Media Registration is granted at the Conference to all bona fide media representatives.

A Press Center will provide you with information, resources, and expert opinion, and you will have access to all the scientific sessions and the Patient Seminar. For more information about the ESEC program and the Patient Seminar, please visit www.esmo.org

For further information, please contact:
Gracemarie Bricalli, ESMO Media Coordinator (Switzerland)
Tel. +41 (0)91 973 19 11, Fax +41 (0)91 973 19 12, gracemarie@esmo.org
Elaine Snell, ESMO Press Office (UK)
Tel. +44 (0)20 7738 0424, Fax +44 (0)20 7978 4494, elaine.snell@which.net
-end-
About the European Society for Medical Oncology (ESMO):
ESMO believes that every cancer patient is entitled to the best possible treatment available. Since medicine is involved in every aspect of cancer therapy, cancer patients need to be treated by qualified medical oncologists. ESMO is the leading European Society that provides education and guidelines for medical oncologists to ensure optimal care for cancer patients. Since 1975, the Society has grown to include representatives from every European country and the six major geographical regions of the world.

European Society for Medical Oncology

Related Oncology Articles from Brightsurf:

Study reveals impact of COVID-19 on oncology staff and their work
A study presented at the NCRI Virtual Showcase reports the results of a survey of oncology staff on their management of patients, their wellbeing and whether they felt valued during the first wave of the COVID-19 pandemic.

Study of COVID-19 levels in oncology staff suggests need for more extensive testing
A study of oncology staff carried out immediately after the spring peak of the COVID-19 pandemic in the UK indicates that many had been infected with the coronavirus as they tested positive for COVID-19 antibodies.

Troubled independent oncology practices in COVID-19 era
The financial risks and challenges for independent oncology practices in the COVID-19 era and possible solutions to promote their stability and survival are discussed in this Viewpoint.

FDA support for oncology drug development during COVID-19
This Viewpoint from the U.S. Food and Drug Administration puts into context recent guidance on clinical trials during COVID-19 for oncology and shares insight regarding regulatory challenges and lessons learned.

Novel immune-oncology approach for potential cancer treatment
A research collaboration between Monash University and Lava Therapeutics details a novel immune-oncology approach for the potential treatment of cancer.

ModGraProDep: Artificial intelligence and probabilistic modelling in clinical oncology
Improving the prediction of survival indicators in patients with breast cancer using tools from artificial intelligence and probabilistic modelling is the aim of ModGraProDep, an innovative system presented in a study led by Ramon Clèries, lecturer at the Department of Clinical Sciences of the Faculty of Medicine and Health Sciences of the University of Barcelona and member of the Oncology Master Plan/ICO-IDIBELL.

Better outcomes, lower cost in first-ever oncology hospital at home evaluation
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) presented the first outcomes evaluation of an adult oncology hospital-at-home program today at the 2020 American Society of Clinical Oncology (ASCO) annual meeting.

Hippocampal avoidance during WBRT reduces risks on NRG Oncology trial
Results from the NRG Oncology clinical study NRG-CC001 concluded that lowering radiotherapy dose to hippocampal stem cells improves cognitive and patient-reported outcomes for patients with brain metastases.

Dozens of non-oncology drugs can kill cancer cells
Researchers tested approximately 4,518 drug compounds on 578 human cancer cell lines and found nearly 50 that have previously unrecognized anti-cancer activity.

10-year results of NRG Oncology/NSABP B-42 trial
In the updated results from NRG Oncology/NSABP B-42 trial through 10 years of observation, extending letrozole therapy for additional five years after five years of adjuvant endocrine therapy resulted in a statistically significant improvement in the 10-year disease-free survival (DFS) of postmenopausal women with hormone-receptor-positive breast cancer.

Read More: Oncology News and Oncology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.